Limiting the priming dose of a SARS CoV-2 vaccine improves virus-specific immunity

Since late 2019, SARS-CoV-2 has caused a global pandemic that has infected 128 million people worldwide. Although several vaccine candidates have received emergency use authorization (EUA), there are still a limited number of vaccine doses available. To increase the number of vaccinated individuals,...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanchez, Sarah, Palacio, Nicole, Dangi, Tanushree, Ciucci, Thomas, Penaloza-MacMaster, Pablo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020975/
https://www.ncbi.nlm.nih.gov/pubmed/33821275
http://dx.doi.org/10.1101/2021.03.31.437931

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020975/
https://www.ncbi.nlm.nih.gov/pubmed/33821275
http://dx.doi.org/10.1101/2021.03.31.437931

Ejemplares similares